Multicenter, pilot study to assess the safety and efficacy of Lenalidomide and Ofatumumab combination (Lenofa) in chronic lymphocytic leukenia (CLL) patients relapsed or refractory after fludarabine containing regimens" Multicenter, pilot study to assess the safety and efficacy of Lenalidomide and Ofatumumab combination (Lenofa) in chronic lymphocytic leukenia (CLL) patients relapsed or refractory after fludarabine containing regimens

Trial Profile

Multicenter, pilot study to assess the safety and efficacy of Lenalidomide and Ofatumumab combination (Lenofa) in chronic lymphocytic leukenia (CLL) patients relapsed or refractory after fludarabine containing regimens" Multicenter, pilot study to assess the safety and efficacy of Lenalidomide and Ofatumumab combination (Lenofa) in chronic lymphocytic leukenia (CLL) patients relapsed or refractory after fludarabine containing regimens

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Ofatumumab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms LenOfa-CLL
  • Sponsors Celgene International SARL
  • Most Recent Events

    • 25 Mar 2016 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 03 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top